(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ganesh Raghu, MD
University of Washington, Div. of Pulmonary and Critical Care Medicine Chair
Study ChairKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
185 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Mar del Plata, Buenos Aires, Argentina
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Mar Del Plata, Buenos Aires, Argentina
- Facility name not stated
San Miguel de Tucumán, Argentina
- Facility name not stated
Concord, New South Wales, Australia
- Facility name not stated
Darlinghurst, New South Wales, Australia
- Facility name not stated
Chermside, Queensland, Australia
- Facility name not stated
Woodville, South Australia, Australia
- Facility name not stated
Hobart, Tasmania, Australia
- Facility name not stated
Parkville, Victoria, Australia
- Facility name not stated
Prahran, Victoria, Australia
- Facility name not stated
Perth, Western Australia, Australia
- Facility name not stated
Graz, Austria
- Facility name not stated
Innsbruck, Austria
- Facility name not stated
Linz, Austria
- Facility name not stated
Vienna, Austria
- Facility name not stated
Anderlecht, Belgium
- Facility name not stated
Brussels, Belgium
- Facility name not stated
Leuven, Belgium
- Facility name not stated
Yvoir, Belgium
- Facility name not stated
São Paulo, São Paulo, Brazil
- Facility name not stated
Belo Horizonte, Brazil
- Facility name not stated
Florianópolis, Brazil
- Facility name not stated
Goiânia, Brazil
- Facility name not stated
Porto Alegre, Brazil
- Facility name not stated
Porto Alegre, Brazil
- Facility name not stated
Porto Alegre, Brazil
- Facility name not stated
Rio de Janeiro, Brazil
- Facility name not stated
Santo André, Brazil
- Facility name not stated
Calgary, Alberta, Canada
- Facility name not stated
Edmondton, Alberta, Canada
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
St. John's, Newfoundland and Labrador, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Sainte-Foy, Quebec, Canada
- Facility name not stated
Toronto, Canada
- Facility name not stated
Santiago, Chile
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2008
- Primary completion
- 28 Feb 2011
- Completion
- 28 Feb 2011
- Last update posted
- 8 Apr 2014
- Registered enrollment
- 494
- Registry id
- NCT00768300
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.